Analysts: Isis-Lilly deal validates antisense.
Niiler
E
E
D000970:Antineoplastic Agents / Q000191:economics*; D001709:Biotechnology / Q000191:economics* / Q000458:organization & administration; D004345:Drug Industry / Q000191:economics* / Q000458:organization & administration; D004791:Enzyme Inhibitors / Q000191:economics; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D020319:Oligodeoxyribonucleotides, Antisense / Q000191:economics*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D051571:Protein Kinase C-alpha; D013873:Thionucleotides / Q000191:economics*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D020319:Oligodeoxyribonucleotides, Antisense; D013873:Thionucleotides; C108494:ISIS 3521; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha